LA JOLLA, Calif. - Geneticists at the Salk Institute introduced Superb-seq on Nov. 16 in Nature Methods, a single-cell technique that maps both intended and unintended CRISPR DNA edits alongside resulting changes in gene activity.
Leukemia Cell Test Flags 36 Off-Target Sites
While CRISPR/Cas9 acts as molecular scissors for targeted therapies, off-target cuts can alter unintended DNA regions, and older methods could not link those errors to individual cell behavior. Across 34,000 tested cells from three cell lines, Superb-seq examined 10,000 human leukemia cells and detected 5,761 edited cells and 43 edit sites, 36 of which were off-target.
"I knew off-targets were an issue, but they were far more frequent than I was expecting," senior author Graham McVicker said in a Salk Institute news release, adding that the extent of the problem will surprise many lab researchers.
Tool Separates Benign From Harmful Errors
Co-first author Brad Balderson noted that off-target edits can disrupt genes protecting against cancer, making it vital to distinguish benign changes from dangerous ones inside specific cells. Unlike its predecessor Perturb-seq, which reads guide RNAs without capturing actual DNA edits, Superb-seq directly links single-cell edits to gene expression.
Patent Filed for Therapy and AI Data Use
McVicker and colleagues have filed a patent for Superb-seq, envisioning applications in preclinical gene-therapy safety screening, personalized treatment selection, and generating higher-quality single-cell training data for artificial intelligence models of cellular function.



